TAKEDA PHARMACEUTICAL CO LTD current report, Q1 FY2023

Full document

Takeda Pharmaceutical Co Ltd - Form 6-K Summary

Business Context and Reporting Period

This filing reports the consolidated financial results for Takeda Pharmaceutical Company Limited for the nine-month period ended December 31, 2022 (April 1 to December 31, 2022). The report was filed on February 2, 2023. Takeda applies International Financial Reporting Standards (IFRS).

Key Financial Metrics

Metric 9 Months Ended Dec 31, 2022 9 Months Ended Dec 31, 2021 Change (%)
Revenue 3,071,322 Million JPY 2,695,717 Million JPY +13.9%
Operating Profit 401,943 Million JPY 462,463 Million JPY -13.1%
Profit Before Tax 327,175 Million JPY 356,618 Million JPY -8.3%
Net Profit (Period) 285,903 Million JPY 241,541 Million JPY +18.4%
Net Profit (Attributable to Owners) 285,883 Million JPY 241,417 Million JPY +18.4%
Basic EPS 184.32 JPY 154.09 JPY +19.6%
Core Operating Profit 954.7 Billion JPY 757.9 Billion JPY +26.0%
Core EPS 456 JPY 333 JPY +37.0%

Balance Sheet and Cash Flow

  • Total Assets: 13,504,705 Million JPY (as of Dec 31, 2022), an increase of 326.7 Billion JPY from the prior fiscal year-end.
  • Total Equity: 6,176,498 Million JPY, with an equity ratio of 45.7%.
  • Debt: Bonds and loans decreased to 4,286.9 Billion JPY, driven by bond redemptions.
  • Cash Flow:
    • Net cash from operating activities: 683.5 Billion JPY (decrease of 64.1 Billion JPY YoY).
    • Net cash used in investing activities: 168.6 Billion JPY.
    • Net cash used in financing activities: 702.5 Billion JPY.
    • Cash and cash equivalents at period end: 685.1 Billion JPY.

Material Changes and Drivers

  • Revenue Growth: Driven by business momentum in core therapeutic areas (GI, Rare Diseases, PDT Immunology, Neuroscience) and favorable foreign exchange rates. This offset a 133.0 Billion JPY decrease due to the sale of the diabetes portfolio in Japan recorded in the prior year.
  • Operating Profit Decline: Despite revenue growth, operating profit fell 13.1% due to increased R&D expenses, SG&A, and amortization/impairment charges, largely impacted by the depreciation of the yen.
  • Net Profit Increase: Net profit rose 18.4% primarily due to a significant decrease in income tax expenses (down 64.1% YoY) compared to a large tax charge in the prior year related to the Shire acquisition break fee.
  • Therapeutic Area Performance:
    • GI: +28.8% (driven by ENTYVIO).
    • Rare Diseases: +19.6% (driven by TAKHZYRO).
    • PDT Immunology: +38.3% (strong demand for immunoglobulins).
    • Oncology: -3.9% (impacted by generic erosion of VELCADE).
    • Neuroscience: +31.6% (driven by VYVANSE/ELVANSE).

Guidance, Outlook, and Risks

  • Full Year Forecast (FY Ending March 31, 2023): Unchanged from the October 2022 announcement.
    • Revenue: 3,930 Billion JPY (+10.1%).
    • Operating Profit: 530 Billion JPY (+15.0%).
    • Net Profit: 307 Billion JPY (+33.4%).
    • Core Operating Profit: 1,180 Billion JPY (+23.5%).
  • Management Guidance (Core Growth at CER):
    • Core Revenue: Low-single-digit growth.
    • Core Operating Profit: High-single-digit growth.
    • Core EPS: High-single-digit growth.
  • Risks and Contingencies:
    • Geopolitical: Takeda has discontinued non-essential activities in Russia. Revenue from Russia/CIS was 2.2% of total revenue in the period. No material financial impact reported to date, but future results could be adversely affected.
    • COVID-19: Forecast includes approx. 50.0 Billion JPY revenue from COVID-19 vaccines (NUVAXOVID, SPIKEVAX).
    • FX Rates: Forecasts assume specific exchange rates (e.g., 1 USD = 132 JPY); fluctuations could impact results.

Investor Verification Checklist

  • Verify the impact of the yen depreciation on reported vs. constant exchange rate (CER) performance.
  • Confirm the sustainability of Core Operating Profit growth given the decline in reported operating profit.
  • Monitor the generic erosion of key Oncology products (specifically VELCADE) and its long-term impact on the segment.
  • Review the tax expense volatility, noting the one-time nature of the prior year's Shire-related tax charge.
  • Assess the cash flow position relative to the significant bond redemptions and dividend payments (278.3 Billion JPY paid in the period).
  • Check for updates on the Ukraine/Russia crisis impact on supply chains and revenue in the Russia/CIS region.